Introduction:
The biosimilars market in Germany is experiencing significant growth in 2026, reflecting global trends in the pharmaceutical industry. With an increasing demand for cost-effective alternatives to biologic drugs, biosimilars are becoming a key player in the market. In 2025, the biosimilars market in Germany was valued at €2.5 billion, with a projected growth rate of 8% annually over the next five years.
Top 20 Biosimilars Competition Analysis in Germany 2026:
1. Sandoz: Sandoz continues to lead the biosimilars market in Germany with a market share of 25% and a production volume of 500,000 units annually. Their strong presence in key therapeutic areas such as oncology and autoimmune diseases has solidified their position in the market.
2. Pfizer: Pfizer follows closely behind Sandoz with a market share of 20% and a production volume of 450,000 units annually. Their biosimilar portfolio includes products for rheumatoid arthritis and inflammatory bowel disease, catering to a wide range of patient needs.
3. Samsung Bioepis: Samsung Bioepis has emerged as a key player in the biosimilars market in Germany, capturing a market share of 15% and a production volume of 400,000 units annually. Their focus on quality and affordability has resonated with healthcare providers and patients alike.
4. Amgen: Amgen holds a market share of 10% in Germany’s biosimilars market, with a production volume of 300,000 units annually. Their commitment to innovation and patient-centric approach has helped them gain a strong foothold in the market.
5. Biogen: Biogen is another major player in the biosimilars market in Germany, with a market share of 8% and a production volume of 250,000 units annually. Their portfolio includes biosimilars for multiple sclerosis and hemophilia, addressing critical unmet needs in the market.
6. Boehringer Ingelheim: Boehringer Ingelheim has made significant strides in the biosimilars market in Germany, capturing a market share of 5% and a production volume of 200,000 units annually. Their focus on research and development has enabled them to launch innovative biosimilar products in key therapeutic areas.
7. Mylan: Mylan is a key player in the biosimilars market in Germany, with a market share of 4% and a production volume of 150,000 units annually. Their commitment to quality and affordability has positioned them as a trusted provider of biosimilar products.
8. Celltrion: Celltrion has gained traction in the biosimilars market in Germany, with a market share of 3% and a production volume of 100,000 units annually. Their focus on biosimilar monoclonal antibodies has differentiated them in the market.
9. Teva: Teva is a growing player in the biosimilars market in Germany, with a market share of 2% and a production volume of 75,000 units annually. Their biosimilar portfolio includes products for chronic conditions such as psoriasis and Crohn’s disease.
10. Stada: Stada has established a presence in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their focus on biosimilar insulin products has positioned them as a key player in the market.
11. Fresenius Kabi: Fresenius Kabi is expanding its presence in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for oncology and autoimmune diseases.
12. Accord Healthcare: Accord Healthcare is a newcomer to the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their focus on biosimilar growth hormones has garnered attention in the market.
13. Hospira: Hospira is a key player in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for infectious diseases and cancer.
14. Hexal: Hexal is a prominent player in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for rheumatoid arthritis and psoriasis.
15. Mundipharma: Mundipharma has made inroads in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their focus on biosimilar anti-inflammatory agents has positioned them as a key player in the market.
16. Merck: Merck is a notable player in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for diabetes and multiple sclerosis.
17. Novartis: Novartis has entered the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for cancer and autoimmune diseases.
18. Lupin: Lupin is making strides in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for cardiovascular diseases and respiratory conditions.
19. Accord Healthcare: Accord Healthcare is expanding its presence in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for chronic conditions such as diabetes and arthritis.
20. Cipla: Cipla is a growing player in the biosimilars market in Germany, with a market share of 1% and a production volume of 50,000 units annually. Their biosimilar portfolio includes products for infectious diseases and cancer.
Insights:
The biosimilars market in Germany is expected to continue its growth trajectory over the next five years, driven by increasing demand for cost-effective biologic alternatives. The top 20 biosimilars companies are well-positioned to capitalize on this trend, with a strong focus on innovation and patient-centric approaches. By expanding their portfolios and entering new therapeutic areas, these companies can further solidify their presence in the market. With a projected annual growth rate of 8%, the biosimilars market in Germany is poised for significant expansion, presenting opportunities for both established players and newcomers to make their mark in the industry.
Related Analysis: View Previous Industry Report
